Home Online Advertising With Pharma’s Ability To Target Limited, Precision Health Prescribes Regimen Of Context And Geography

With Pharma’s Ability To Target Limited, Precision Health Prescribes Regimen Of Context And Geography

SHARE:

Precision Health Media is one of a large number of ad tech companies that began life as a vertical ad network and have been trying to evolve into a broader “platform.” The New York-based company still has many of the attributes of an ad network — it was initially known as Good Health Media when it was launched four years ago with ad serving powered by Adify — such as representing 280 health sites.

As the company looks to build out some self-serve ad functions next year, the concentration right now involves sharpening its focus as a contextual/semantic provider, promising to match advertisers and agencies with sites that have shown they can directly reach allergy sufferers or those afflicted by, or deeply interested in, specific diseases like diabetes or multiple sclerosis.

“If a brand just wanted to reach those consumers looking into type-1 diabetics, we could find that kind of content by going through the 280 sites in our system,” says Bill Jennings, Precision Health’s CEO, in an interview with AdExchanger. “But we don’t just rely on semantics. For example, with diabetes, there happens to be an obvious belt of six or seven states with a higher than average incidence of the disease, so we’ll test inventory heavily against site readers in those areas. With pollen count, it’s the same thing, as we’ll target placements to readers in locations where allergy issues are trending.”

For the most part, behavioral targeting is off-limits to pharmaceutical marketers, Jennings notes. On average, Precision Health claims that its ConditionMatch contextual ad product delivers a click-through rate 40 percent higher than the industry average. It also claims that tests by a “major pharmaceutical marketer” — it wouldn’t identify the company — showed that ConditionMatch lowered cost-per-visit by 71 percent. Furthermore, Jennings points to ConditionMatch’s use of four years worth of site data, which allows the company to track the historical performance of a particular URL when it runs a specific kind of ad.

“The Interactive Advertising Bureau and other groups have agreed that drug companies should be tracking consumers’ illnesses or medical problems directly. It makes sense. And from a practical standpoint, it forces advertisers to do better forms of targeting to get to the right audience. For example, our advertisers are up to 50 percent more likely to reach a consumer who has filled a prescription when compared to targeting general health portals, such as WebMD.”

One of the biggest problems agencies with niche health conditions have is finding enough inventory. Again, because of the limited behavioral targeting options, audience buying is hindered to some extent. “If you think about conditions like gout, COPD, or MS, they might have to contact 12 to 18 sites individually to find the inventory. So we’re positioning ConditionMatch as a way to aggregate our sites’ collective 57 million monthly users and become a one-stop shop for media buyers.”

Must Read

HUMAN Expands Its IVT Detection Tool Kit With A New Product For Advertisers, Not Platforms

HUMAN has recently started complementing its bid request analysis by analyzing the time between when a bot clicks an ad and when the landing page loads. Now it’s offering the solution to individual advertisers.

Index Exchange Launches A Data Marketplace For Sell-Side Curation

Through Index Exchange’s data vendor marketplace, curators gain access to third-party data sets without needing their own integrations.

Can Publishers Trust The Trade Desk’s New Wrapper?

TTD says OpenAds is not just a reaction to Prebid’s TID change, but a new model for fairer, more transparent ad auctions. So what does the DSP need to do to get publishers to adopt its new auction wrapper?

Privacy! Commerce! Connected TV! Read all about it. Subscribe to AdExchanger Newsletters

Scott Spencer’s New Startup Wants To Help Users Monetize Their Online Advertising Data

What happens when an ad tech developer partners with a cybersecurity expert to start a new company? You end up with a consumer product that is both a privacy software service and a programmatic advertising ID.

Former FTC commissioner Alvaro Bedoya speaks to AdExchanger Managing Editor Allison Schiff at Programmatic IO NY 2025.

Advertisers Probably Shouldn’t Target Teens At All, Cautions Former FTC Commissioner

Alvaro Bedoya shared his qualms with digital advertising’s more controversial targeting tactics and how kids use gen AI and social media.

Wall Street Turned Against Ad Tech – But May Learn To Love It Again

What can pureplay ad tech companies do to clean up their rep on the Street?